πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

111 results for β€œChongqing” Clear

  1. 1.0mg/kg/day PRAX-562

    Chongqing Precision Biotech Co., Ltd

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial
  2. 18F fluciclovine

    Chongqing Precision Biotech Co., Ltd

    Brain Metastases

    phase 3 small molecule completed

    2 trials
  3. 1mg elsunersen

    Chongqing Precision Biotech Co., Ltd

    Epileptic Encephalopathy

    phase 3 small molecule active

    1 trial
  4. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Seizure

    phase 3 small molecule active

    1 trial
  5. 40 mg/day vormatrogine for 12 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  6. 60 mg ulixacaltamide

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 3 small molecule active

    1 trial
  7. Early Vasopressin

    Chongqing Precision Biotech Co., Ltd

    Septic Shock

    phase 3 small molecule active

    1 trial
  8. ICT-107

    Chongqing Precision Biotech Co., Ltd

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials
  9. PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  10. PRAX-222

    Chongqing Precision Biotech Co., Ltd

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial
  11. PRAX-562

    Chongqing Precision Biotech Co., Ltd

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial
  12. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial
  13. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  14. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  15. metronomic adjuvant chemotherapy with capecitabine

    Chongqing Claruvis Pharmaceutical Co.,

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial
  16. vormatrogine

    Chongqing Precision Biotech Co., Ltd

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial
  17. 10 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial
  18. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule terminated

    1 trial
  19. 100 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial
  20. 30mg PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial
  21. 60 mg PRAX-114 or 40 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial
  22. Atorvastatin Oral Tablet

    Chongqing Precision Biotech Co., Ltd

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial
  23. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials
  24. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources